NeuroHeal Biomedicals will advance the development of a new drug to restore peripheral nerve well function. The objective of the company is to initiate clinical trials in humans within two years
The research team led by Dr. Caty Casas, from the Institut de Neurociències of the Universitat Autònoma de Barcelona (INc-UAB), has created the company NeuroHeal Biomedicals to develop a new neuroprotective treatment that also accelerates the regeneration of damaged peripheral nerves.
COST (European Cooperation in Science and Technology) is a pan-European intergovernmental framework. Its mission is to enable break-through scientific and technological developments leading to new concepts and products and thereby contribute to strengthening Europe’s research and innovation capacities. www.cost.eu
COST is supported by EU Framework Programme Horizon 2020.
TRANSAUTOPHAGY COST ACTION
Neuroscience Institute, Faculty of Medicine Universitat Autónoma de Barcelona